Myers cocktail IVs: FDA status, evidence, and the 2026 recall
A Myers cocktail is not one standardized FDA-approved drug. Formulas, compounders, concentrations, sterility controls, claims, and evidence vary. The September 2026 recall applies to specified Centric Compounding lots—not to every Myers cocktail.
A Myers cocktail is a variable intravenous micronutrient formula, not one standardized FDA-approved drug. Approval of an individual vitamin or mineral for another product or route does not approve the mixed IV bag or its wellness claims. FDA’s September 13, 2026 posting concerns Centric Compounding’s voluntary recall of six specified lots—including two labeled “Myer’s Cocktail”—for elevated endotoxin; it does not recall every Myers cocktail.12
The name is not a recipe
Clinics may use “Myers,” “Myer’s,” or “modified Myers” for mixtures containing different amounts and forms of magnesium, calcium, vitamin C and B vitamins, with possible added ingredients. Total volume, diluent, pH, osmolality, concentration, infusion time and route also differ. Two menu items with the same name may not be the same drug preparation.
Before payment, request the exact written formula for the bag that would be administered—not a sample menu. Every active and inactive ingredient should have a concentration, amount, source and purpose.
| Record | What it establishes | What it does not establish |
|---|---|---|
| Ingredient is present in an approved drug | That an approved product containing it exists | Approval of this compounded mixture, route or claim |
| Pharmacy license or 503B registration | A current entity record with a defined role | Approval of each finished bag or freedom from recalls |
| Lot and label | Traceability to a particular preparation | Sterility, potency or clinical benefit by itself |
| Recall match | Whether an exact product/lot is in a current notice | A category-wide finding about all Myers cocktails |
| Small clinical study | Evidence for its tested formula, population and outcome | Proof for every wellness or disease claim |
Read the 2026 recall at lot level
Centric Compounding voluntarily recalled six lots nationwide after elevated endotoxin testing, including Myer’s Cocktail lots 070226:D and 072126:A. FDA’s posting reports nine adverse events and describes potential reactions to injected endotoxin, including fever, low blood pressure, inflammatory responses and severe outcomes.1
The correct response is traceability:
- compare the dispensing or administration label with the company, product and lot in the notice;
- follow the recall’s recipient instructions;
- contact the named pharmacy/clinic through independently verified information; and
- seek clinical guidance for symptoms rather than using a category-wide social post.
Do not infer that a bag is affected because its color or ingredients look similar. Do not infer that a different lot is safe solely because it is absent from one notice; normal receiving, storage, label and quality checks still apply.
Compounding status is not product approval
An individualized compound can address a documented clinical need, but the finished IV bag does not receive FDA approval or premarket assessment of safety, effectiveness and quality.2 Treat the pharmacy license, registration, inspection history and any certificate as separate records; none is a surrogate approval for the cocktail.
Sterile injections require more than correct ingredient math. The chain includes source components suitable for the intended use, aseptic operations, sterility assurance, endotoxin control, container closure, storage, shipping and handling at the clinic. A certificate of analysis for one ingredient does not certify the finished bag.
Evidence must match the formula and promised outcome
The placebo-controlled pilot most often cited studied 34 adults with fibromyalgia and compared intravenous micronutrients with lactated Ringer’s solution. It did not find a statistically significant between-group difference and concluded that efficacy remained uncertain.4 That small study cannot validate immune boosting, detoxification, energy, migraine, infection prevention or a generic wellness benefit.
FTC previously challenged unsupported disease-treatment claims by an IV-cocktail marketer, including claims involving Myers cocktail, and entered a final order requiring appropriate evidence for health claims.3 The lesson is not that IV vitamins can never be medically indicated. It is that the claim, exact formula, population and quality of evidence must connect.
Ask what measurable problem is being treated, why the intravenous route is necessary, which trial studied the same preparation and what would count as nonresponse. A testimonial is not a comparator, and feeling different immediately after fluids does not identify which ingredient caused the change or whether it persists.
Intravenous delivery adds its own hazards
An IV bypasses gastrointestinal barriers and creates risks related to venous access, infection, infiltration, dose, concentration, infusion rate, fluid load, electrolyte shifts, allergy and formulation quality. History should include kidney and heart conditions, pregnancy, relevant laboratory results, medicines, supplements and prior infusion reactions as appropriate to the formula.
The clinic should identify the licensed prescriber, administrator, monitoring during infusion, emergency supplies, physician availability, transfer pathway and after-hours contact. A mobile setting needs a location-specific emergency and waste plan, not only a branded van or concierge promise.
Price comparisons require the complete bag and care pathway
One “Myers IV” may contain a different volume, formula, pharmacy product and visit structure than another. Compare the same ingredients and amounts, prescriber assessment, supplies, infusion time, monitoring, follow-up, laboratory work, travel or mobile fee, membership commitment and reaction care. A discount package can create pressure to infuse when the indication or formula has changed.
- Replace the menu name with a formula List every ingredient, form, concentration, amount, diluent and total volume.
- Trace the finished preparation Verify compounder, status, label, lot, beyond-use date, storage and shipping—not only ingredient brands.
- Check current recalls Match company, product and lot exactly; preserve the notice date and any updates.
- Audit the claim Demand route- and formula-matched evidence for one measurable outcome and a finite reassessment.
- Inspect infusion readiness Confirm licensed roles, monitoring, emergency response, records and after-hours ownership.
The durable rule is product specificity. Neither a recall headline nor an “FDA-approved vitamin” statement can substitute for the exact bag, lot, evidence and accountable clinical pathway.
Sources
- U.S. Food and Drug Administration. Centric Compounding recall of glutathione, Myer's Cocktail, and Tri-Immune Boost. September 2026 company recall posted by FDA covering six specified lots, including two Myer's Cocktail lots, because of elevated endotoxin. Accessed .
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. FDA explanation that compounded drugs are not FDA approved and are not reviewed before marketing like approved drugs. Accessed .
- Federal Trade Commission. iV Bars matter. FTC enforcement and final order addressing unsupported disease-treatment claims for IV cocktails including Myers cocktail. Accessed .
- PubMed Central. Intravenous micronutrient therapy for fibromyalgia: placebo-controlled pilot study. Small randomized pilot in 34 adults finding no statistically significant between-group difference and leaving efficacy uncertain. Accessed .